Publication – Parkinson Disease
Marcellino, D.; Suárez-Boomgaard, D.; Sánchez-Reina, M.D.; Aguirre, J.A.; Yoshitake, T.; Yoshitake, S.; Hagman, B.; Kehr, J.; Agnati, L.F.; Fuxe, K.; Rivera, A. On the role of P2X(7) receptors in dopamine nerve cell degeneration in a rat model of Parkinson's disease: studies with the P2X(7) receptor antagonist A-438079. J Neural Transm 2010, 117, 681-687.
Galter, D.; Pernold, K.; Yoshitake, T.; Lindqvist, E.; Kehr, J.; Olson, L. MitoPark mice mirror the slow progression of key Parkinson disease symptoms and the L-DOPA response. Genes, Brain and Behavior 2010, 9, 173-181.
Herrera-Marschitz, M.; Bustamante, D.; Morales, P.; Goiny, M. Exploring neurocircuitries of the basal ganglia by intracerebral administration of selective neurotoxins. Neurotox Res 2007, 11(3-4), 169-82.
Kehr, J.; Hu, X.J.; Goiny, M.; Scheller, D.K. Continuous delivery of rotigotine decreases extracellular dopamine suggesting continuous receptor stimulation. J Neural Transm 2007, 114, 1027-1031.
Kehr, J.; Hu, X.J.; Yoshitake, T.; Scheller, D. Determination of the dopamine agonist rotigotine in microdialysates from the rat brain by microbore column liquid chromatography with electrochemical detection. J Chromatogr B Analyt Technol Biomed Life Sci 2007, 845, 109-113.
Aguirre, J.A.; Kehr, J.; Yoshitake, T.; Liu, F.L.; Rivera, A.; Fernandez-Espinola, S.; Andbjer, B.; Leo, G.; Medhurst, A.D.; Agnati, L.F.; Fuxe, K. Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP. Brain Res 2005, 1033, 216-20.
Tanganelli, S.; Sandager Nielsen, K.; Ferraro, L.; Antonelli, T.; Kehr, J.; Franco, R.; Ferre, S.; Agnati, L.F.; Fuxe, K.; Scheel-Kruger, J. Striatal plasticity at the network level. Focus on adenosine A(2A) and D(2) interactions in models of Parkinson's Disease. Parkinsonism Relat Disord 2004, 10, 273-80.
Bustamante, D.; Bustamante, L.; Segura-Aguilar, J.; Goiny, M.; Herrera-Marschitz, M. Effects of the DT-diaphorase inhibitor dicumarol on striatal monoamine levels in L-DOPA and L-deprenyl pre-treated rats. Neurotox Res. 2004 5(8):569-77
